Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 9/20 | 0.49 |
| ▸ | AR | P10275 | 1/20 | 0.47 |
| ▸ | ESR1 | P03372 | 8/20 | 0.43 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.42 |
| ▸ | MAOA | P21397 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.39 |
| ▸ | APP | P05067 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | MIF | P14174 | 1/20 | 0.38 |
| ▸ | ERN1 | O75460 | 1/20 | 0.38 |
| ▸ | ESRRB | O95718 | 1/20 | 0.37 |
| ▸ | ESRRA | P11474 | 1/20 | 0.37 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.37 |
| ▸ | CASR | P41180 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1532431 | 0.78 | ESR2 (0.61) | ESR2ARESR1CYP19A1MAOA | |
| SCHEMBL1765495 | 0.76 | ESR2 (0.61) | ESR2ESR1MAOAMAOBAPP | |
| SCHEMBL24838568 | 0.76 | ESR2 (0.59) | ESR2ERBB2CYP3A4 | |
| SCHEMBL17707901 | 0.75 | ESR1 (0.50) | ESR2ARESR1APPCYP3A4 | |
| SCHEMBL21180012 | 0.73 | ERBB2 (0.46) | ARMAOAMAOBERBB2ERN1 | |
| SCHEMBL4667162 | 0.73 | ESR2 (0.59) | ESR2ARESR1CYP19A1MAOA | |
| SCHEMBL13748783 | 0.72 | AR (0.42) | ESR2ARESR1APPCYP3A4 | |
| SCHEMBL10593081 | 0.72 | TRPA1 (0.53) | ESR2ESR1APPCYP3A4CYP2C9 | |
| SCHEMBL29634557 | 0.72 | LMNA (0.50) | ESR2ESR1APPCYP3A4CYP2C9 | |
| SCHEMBL2868070 | 0.72 | LMNA (0.50) | ESR2ESR1APPCYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8609892-B2 | Glucagon receptor antagonists, preparation and therapeutic uses | ELI LILLY AND COMPANY (US) | 2013-12-17 | — | — | US | disclosed |
| US-20110124648-A1 | GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES | ELI LILLY AND COMPANY (US) | 2011-05-26 | — | — | US | disclosed |
| US-20100324140-A1 | GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES | ELI LILLY AND COMPANY (US) | 2010-12-23 | — | — | US | disclosed |
| US-7816557-B2 | 3-{4-[1-(4'-tert-butyl-2,6-dimethyl-biphenyl-4-yloxy)-4,4,4-trifluoro-butyl]-benzoylamino}-propionic acid; treat diabetic and other glucagon related metabolic disorders | ELI LILLY AND COMPANY (US) | 2010-10-19 | — | — | US | disclosed |
| EP-2159221-A1 | Glucagon receptor antagonists, preparation and therapeutic uses | Eli Lilly & Company (US) | 2010-03-03 | — | — | EP | disclosed |
| EP-1758853-B1 | GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES | LILLY CO ELI (US) | 2010-01-20 | — | — | EP | disclosed |
| US-20070249688-A1 | Glucagon Receptor Antagonists, Preparation and Therapeutic Uses | ELI LILLY AND COMPANY (US) | 2007-10-25 | — | — | US | disclosed |
| EP-1758853-A1 | GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES | ELI LILLY AND COMPANY (US) | 2007-03-07 | — | — | EP | disclosed |
| WO-2005123668-A1 | GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES | ELI LILLY AND COMPANY (US) | 2005-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110124648-A1 | GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES | GLP1R, GCGR, GIPR | ESR2 211/4885AR 287/4885ESR1 236/4885 |
| US-20070249688-A1 | Glucagon Receptor Antagonists, Preparation and Therapeutic Uses | GLP1R, GCGR, GIPR | ESR2 211/4885AR 287/4885ESR1 236/4885 |
| US-20100324140-A1 | GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES | GLP1R, GCGR, GIPR | ESR2 211/4885AR 287/4885ESR1 236/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.